Three things to know:
1. The multi-center trial will investigate ProChondrix CR for the repair of symptomatic articular cartilage defects on the femoral condyle and the patella.
2. ProChondrix CR is a cryopreserved osteochondral allograft. After cryopreservation, ProChondrix CR is designed to deliver high chondrocyte viability for up to two years and help stimulate hyaline cartilage growth.
3. ProChondrix CR’s extracellular matrix is intended to provide structural support for cell migration and proliferation along the graft-native tissue line, promoting integration while viable chondrocytes promote cartilage repair by generating proteins that facilitate chondrogenesis.
More articles on biologics:
SpinalCyte receives new regenerative medicine patents: 5 insights
New bone grafting policy includes Cerapedics’ peptide enhanced bone graft — 3 insights
Aesculap Biologics reaches halfway mark in clinical trial for knee articular cartilage defects: 5 insights
